Date published: 2025-12-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

7-Ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin (CAS 185304-42-1)

0.0(0)
Write a reviewAsk a question

Application:
CAS Number:
185304-42-1
Molecular Weight:
518.56
Molecular Formula:
C28H30N4O6
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

7-Ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin is a potent inhibitor of topoisomerase I, an enzyme involved in DNA replication and transcription. 7-Ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin is a derivative of camptothecin, a alkaloid found in the bark and stem of the Camptotheca acuminata tree. By binding to the topoisomerase I-DNA complex, 7-Ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin prevents the re-ligation of DNA strands, leading to the accumulation of DNA breaks and ultimately cell death.


7-Ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin (CAS 185304-42-1) References

  1. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.  |  Innocenti, F., et al. 2001. Drug Metab Dispos. 29: 596-600. PMID: 11259359
  2. A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4.  |  Sai, K., et al. 2001. Drug Metab Dispos. 29: 1505-13. PMID: 11602529
  3. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.  |  Iyer, L., et al. 2002. Cancer Chemother Pharmacol. 49: 336-41. PMID: 11914914
  4. Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies.  |  Poujol, S., et al. 2003. Clin Chem. 49: 1900-8. PMID: 14578322
  5. Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma.  |  Crews, KR., et al. 2004. J Pediatr Hematol Oncol. 26: 764-7. PMID: 15543015
  6. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38.  |  Charasson, V., et al. 2004. Clin Pharmacol Ther. 76: 528-35. PMID: 15592324
  7. Gefitinib (Iressa) inhibits the CYP3A4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin but activates that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin from irinotecan.  |  Fujita, K., et al. 2005. Drug Metab Dispos. 33: 1785-90. PMID: 16123050
  8. Modulation of cytochrome P450 activity: implications for cancer therapy.  |  Scripture, CD., et al. 2005. Lancet Oncol. 6: 780-9. PMID: 16198984
  9. Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats.  |  Yokoo, K., et al. 2007. Drug Metab Dispos. 35: 1511-7. PMID: 17537871
  10. Quantitation of Irinotecan and its two major metabolites using a liquid chromatography-electrospray ionization tandem mass spectrometric.  |  Zhang, W., et al. 2009. J Chromatogr B Analyt Technol Biomed Life Sci. 877: 3038-44. PMID: 19648066
  11. Evaluation of therapeutics in three-dimensional cell culture systems by MALDI imaging mass spectrometry.  |  Liu, X., et al. 2013. Anal Chem. 85: 6295-302. PMID: 23724927
  12. Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.  |  Wu, H., et al. 2015. Int J Nanomedicine. 10: 1201-9. PMID: 25709442
  13. Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview.  |  Kciuk, M., et al. 2020. Int J Mol Sci. 21: PMID: 32664667
  14. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.  |  Yokokawa, A., et al. 2021. Eur J Drug Metab Pharmacokinet. 46: 317-324. PMID: 33619631

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

7-Ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin, 1 mg

sc-210613
1 mg
$393.00